Strong first half for EBOS with Australian business up 10%.
EBOS has just released its results for the six months to 31 December, with the local operations reporting a 10.1% increase in EBITDA. There were strong contributions across the board, with “sound growth” in Institutional Healthcare, Consumer Products and the Pharmacy businesses.The net profit after tax was NZ$53.9 million for the group.
CEO Patrick Davies said total group revenues were up 4% to NZ$3.1 billion, while the Australian healthcare business grew 6.5% to NZ$2.285 billion. Of particular note was the 25% acquisition of Good Price Pharmacy Warehouse during the period, which had seen strong levels of wholesale conversion resulting in increased sales for the Symbion wholesale business.
During the half EBOS also opened its new pharmacy distribution facility in Keysborough, Melbourne, representing a capital investment of $31 million, which Davies said reflected the company’s long term commitment to the industry.
“Our business model continues to drive the profitable development of the group and is allowing us to continue to pursue opportunities for the benefit of our customers and shareholders,” Davies said.
More information in today’s issue of Pharmacy Daily.
